Dashboard
Manage Tickers

ATNMActinium Pharmaceuticals, Inc.

NYSE actiniumpharma.com


$ 2.38 $ 0.31 (14.76 %)    

Thursday, 08-Aug-2024 15:59:41 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 449.23 $ 13.30 (3.06 %)
DIA $ 395.05 $ 6.75 (1.74 %)
SPY $ 531.28 $ 11.99 (2.31 %)
TLT $ 95.30 $ -0.59 (-0.62 %)
GLD $ 224.00 $ 3.46 (1.57 %)
$ 2.41
$ 2.36 x 100
-- x --
-- - --
$ 1.33 - $ 10.24
1,666,001
na
75.08M
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 04-26-2024 03-31-2024 10-Q
3 03-29-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-25-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 07-30-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 10-23-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 06-30-2020 03-31-2020 10-Q
19 05-08-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 03-15-2019 12-31-2018 10-K
24 11-09-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-16-2018 12-31-2017 10-K
28 11-03-2017 09-30-2017 10-Q
29 08-04-2017 06-30-2017 10-Q
30 05-15-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 10-28-2016 09-30-2016 10-Q
33 07-29-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-11-2016 12-31-2015 10-K
36 10-30-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 03-16-2015 12-31-2014 10-K
40 10-31-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

5hc-wainwright--co-maintains-buy-on-actinium-pharma-lowers-price-target-to-4
5HC Wainwright & Co. Maintains Buy on Acti...
08/06/2024 18:55:45

HC Wainwright & Co. analyst Joseph Pantginis maintains Actinium Pharma (AMEX:ATNM) with a Buy and lowers the price targe...

actinium-pharmaceuticals-q2-2024-gaap-eps-038-beats-043-estimate
Actinium Pharmaceuticals Q2 2024 GAAP EPS ...
08/06/2024 15:44:54

Actinium Pharmaceuticals (AMEX:ATNM) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate o...

maxim-group-maintains-buy-on-actinium-pharma-lowers-price-target-to-5
Maxim Group Maintains Buy on Actinium Phar...
08/06/2024 14:41:30

Maxim Group analyst Jason McCarthy maintains Actinium Pharma (AMEX:ATNM) with a Buy and lowers the price target from $30 to $5.

why-palantir-technologies-shares-are-trading-higher-by-around-10-here-are-20-stocks-moving-premarket
Why Palantir Technologies Shares Are Tradi...
08/06/2024 09:16:05

sp-500-down-over-100-points-actinium-pharmaceuticals-shares-plunge
S&P 500 Down Over 100 Points; Actinium Pha...
08/05/2024 18:39:57

dow-tumbles-950-points-ism-services-pmi-surges-in-july
Dow Tumbles 950 Points; ISM Services PMI S...
08/05/2024 17:07:18

actinium-pharmaceuticals-receives-fda-request-for-additional-studies-on-leukemia-treatment
Actinium Pharmaceuticals Receives FDA Requ...
08/05/2024 15:21:50

FDA rejects Actinium Pharmaceuticals' Phase 3 SIERRA trial for Iomab-B's Biologics License Application due to inadequat...

nasdaq-tumbles-3-tyson-foods-earnings-top-views
Nasdaq Tumbles 3%; Tyson Foods Earnings To...
08/05/2024 14:20:07

fda-determines-that-actinium-pharmaceuticals-phase-3-sierra-trial-is-not-adequate-to-support-a-bla-filing-for-iomab-b-for-relapsed-or-refractory-acute-myeloid-leukemia-despite-its-statistically-significant-primary-endpoint
FDA Determines That Actinium Pharmaceutica...
08/05/2024 11:12:57

Additional head-to-head randomized clinical trial demonstrating overall survival benefit with Iomab-B is required by FDA to sup...

actinium-pharmaceuticals-received-us-patent-extending-into-2040-and-covers-methods-using-iomab-act-for-conditioning-patients-prior-to-the-administration-of-gene-edited-hematopoietic-stem-cell-therapy-to-treat-non-malignant-disorders
Actinium Pharmaceuticals Received U.S. Pat...
08/01/2024 12:15:28

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
07/26/2024 11:41:18

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

actinium-pharmaceuticals-announces-fda-clearance-for-ind-application-to-study-iomab-act-as-targeted-conditioning-prior-to-bone-marrow-transplant-in-sickle-cell-disease-patients
Actinium Pharmaceuticals Announces FDA Cle...
07/25/2024 12:48:18

Collaboration With Columbia University Aims To Broaden Access To Cellular Therapies And Inform Gene Therapy Conditioning Study

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
06/17/2024 14:45:30

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

actinium-presents-data-demonstrating-actimab-a-in-combination-with-leading-menin-inhibitors-with-its-arc-actimab-a-in-acute-myeloid-leukemia-at-2024-eha-congress
Actinium Presents Data Demonstrating Actim...
06/17/2024 12:11:03

- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combi...

actinium-presents-oral-presentation-featuring-improved-outcomes-in-tp53-patients-receiving-iomab-b-in-the-phase-3-sierra-trial-at-eha-2024-annual-congress
Actinium Presents Oral Presentation Featur...
06/14/2024 12:41:05

-  Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone ma...

actinium-highlights-data-from-completed-phase-1b-combination-trial-of-actimab-a--clag-m-in-rr-aml-at-2024-society-of-nuclear-medicine--molecular-imaging-annual-meeting
Actinium Highlights Data From Completed Ph...
06/11/2024 12:32:51

actinium-highlights-mutation-data-from-the-phase-3-sierra-trial-of-iomab-b-and-novel-linker-technology-to-support-solid-tumor-antibody-radiation-conjugate-development-at-the-2024-snmmi-annual-meeting
Actinium Highlights Mutation Data From The...
06/10/2024 12:37:13

Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia i...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
05/21/2024 10:52:03

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

reported-earlier-actinium-to-present-improved-survival-outcomes-in-tp53-positive-patients-at-the-eha-2024-and-long-term-efficacy-results-in-older-patients-receiving-an-iomab-b-led-bone-marrow-transplant-in-the-phase-3-sierra-trial
Reported Earlier, Actinium To Present Impr...
05/15/2024 07:11:21

- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone mar...

stephens--co-initiates-coverage-on-actinium-pharma-with-overweight-rating-announces-price-target-of-25
Stephens & Co. Initiates Coverage On Actin...
05/14/2024 09:55:15

Stephens & Co. analyst Sudan Loganathan initiates coverage on Actinium Pharma (AMEX:ATNM) with a Overweight rating and a...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION